BRANFORD, Conn., Nov. 24, 2021 /PRNewswire/ -- IsoPlexis
Corporation (Nasdaq: ISO), the leader in functional single-cell
proteomics, today announced the company will be participating
virtually in the upcoming Evercore ISI 4th Annual
HealthCONx Conference.
IsoPlexis' management is scheduled to participate in a fireside
chat on Wednesday, December 1 at
6:40 a.m. Pacific Time / 9:40 a.m. Eastern Time. Interested parties may
access a live and archived webcast on the "Investors" section of
the company website at: www.isoplexis.com.
About IsoPlexis
IsoPlexis is leading a new era of functional proteomics. By
identifying our most proteomically active single cells (or
"superhero cells") for the first time, IsoPlexis enables
researchers to connect more directly to in vivo biology and develop
more precise and personalized therapies. IsoPlexis has been named
Top Innovation or Design by The Scientist Magazine, Fierce, BIG
Innovation, Red Dot and multiple others. The IsoPlexis platform is
used globally by researchers, including those at the top 15 global
pharmaceutical companies and at the majority of leading U.S.
comprehensive cancer centers.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isoplexis-to-participate-in-the-evercore-isi-healthconx-conference-301431379.html
SOURCE IsoPlexis